Aldevron’s Post

When dealing with gene editing, delivery technologies are critical to success. As Max Sellman shares from the 2024 ASGCT annual meeting, lipid nanoparticles (LNP) are becoming more widely used as a non-viral delivery technology for #mRNA, with some new breakthroughs emphasizing their potential. https://lnkd.in/gMKzF-qE

Where is your organization now within the Digitalization Map for Cell & Gene Therapy (CGTx) manufacturing? Should you move? It really depends on many factors e.g., scale, type of process issues. Most CGTx companies are moving up from L1/L2, however you have to be clear on the problems you are trying to troubleshoot. For example, despite using Automated Closed Systems, many CGTx manufacturers still face lengthy product cycle time due to frequent operator errors and long batch review process. In such cases, the implementation of a MES would bring in great value. #cellandgenetherapy #digitalization

Fascinating reading from the BioIndustry Association (BIA) on the Cell and Gene Therapy sector in the UK, and what it has done and is doing in support. Some nice case studies too, of which the manufacturing approach for all have been supported by eXmoor Pharma. Funding in the UK is becoming a critical issue for 2024, and it would be a great shame to see innovation, infrastructure, capacity and skills diminish through want of cash. The interaction between academia and industry and the difficulty of getting early phase products through registrational studies and marketing are topics not developed well in the report (and are increasingly important). https://lnkd.in/et4hDAzx #cellandgeneuk

Epoch 52: CRISPR Corner: Monthly Gene Editing Updates Intended to be a light recap of key CRISPR related events from the previous month. Designed to be consumed as a quick scroll with links to deeper dives. https://lnkd.in/dWPihXBQ

[Join us live] 🗓️ Join us tomorrow at the Gene Therapy Development & Manufacturing 2024, where Ažbe Žnidaršič will give his presentation: CIMmultus Monoliths to Accelerate Process Development, Reproducible Scale up and Consistent Manufacturing of AAV. The presentation will enable you to discover reproducible separation of full AAV from non-potent AAV capsids from process development to manufacturing scale by CIMmultus QA HR. 💡 Did you know that CIMmultus SO3 for AAV capture allows 30 % increase in AAV process yield compared to Affinity AAV capture? Register here: https://lnkd.in/gcsme6Bw #AAV #purification #separation #monoliths #processdevelopment #biotech

🌱 Our platform is at the forefront of enhancing AAV vector yields, achieving up to a 100-fold decrease in the cost of upstream processes. This efficiency leap is made possible by utilizing non-GMP controlled environment agriculture (CEA) facilities instead of traditional cGMP facilities, significantly reducing production costs. ❓Why does this matter? ⚕️The shift towards more cost-effective and efficient production methods is crucial for the future of gene therapy manufacturing. Lowering the barriers to high-quality production enables broader access to vital treatments for those in need. #AAV #GeneTherapy #Upstream #Manufacturing #GeneManufacturing #PlantScience #ViralVector #CostEffective #CEA

📲Calling all the last minute registrants! We have over 💯+ attendees and 20+ industry speakers/panelists. Don't miss out! #FOMO #cellandgenetherapy #sanfrancisco #bayarea #SSF #genetherapy #biotechnology #scienceandtechnology #science #research #processdevelopment #largemolecule

Did you know Japan ranks high globally in market sophistication and innovation, offering growth opportunities for the cell and gene therapy (CGT) sector? For #CGT companies contemplating foreign direct investment in Japan’s burgeoning market, there are several crucial considerations. JLL partnered with the Alliance for Regenerative Medicine to develop a whitepaper on aspects for both companies and investors to consider such as supply chain, labor and real estate. Access the whitepaper: #JLLLifeSciences #CellAndGeneTherapy #ARM

As many pharma companies start to shift their focus into 2024 on bringing new gene therapy based molecules from discovery, into more regulated environments, the need for consistent and accurate purity and integrity data is more important than ever. The BioPhase 8800 system has had a massive impact in helping companies in the screening and monitoring of their products, at the same time having the ease of mind knowing they can use the same platform from discovery to QC environments, all with high quality and consistent data. Are you running applications such as; AAV characterization, LNP-mRNA analysis, fast glycan ID and of course traditional CE-SDS? Take a look at the link below and find out what all the buzz is about. ⬇ #sciex #biopharma #ce https://lnkd.in/e6_QcJj4